Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | BAD | Q92934 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393415 | 0.89 | TP53 (0.36) | CES2CES1CA1CA2ALDH1A1 | |
| SCHEMBL572232 | 0.81 | CES2 (0.48) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL4247526 | 0.78 | CES2 (0.50) | CES2CES1CA1CA2RAB9A | |
| SCHEMBL811028 | 0.78 | ALDH1A1 (0.50) | CES2CES1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15540018 | 0.78 | TPMT (0.48) | CA1CA2PTPN1 | |
| SCHEMBL3205731 | 0.78 | CES2 (0.50) | CES2CES1CA1CA2NPC1 | |
| SCHEMBL28364182 | 0.78 | MAPT (0.42) | CA1CA2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6993491 | 0.78 | CES2 (0.55) | CES2CES1PTPN1MEN1KMT2A | |
| SCHEMBL84542 | 0.77 | CES1 (0.46) | CES2CES1CA1CA2RAB9A | |
| SCHEMBL11139683 | 0.77 | CES1 (0.46) | CES2CES1CA1CA2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| CN-115197113-B | Combretastatin A-4 derivative containing thiourea structure, preparation method and application thereof | 南通大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-115197113-A | Combretastatin A-4 derivative containing thiourea structure, preparation method and application thereof | 南通大学 | 2022-10-18 | — | — | CN | disclosed |
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-02 | — | — | US | disclosed |
| US-20200361860-A1 | hTERT MODULATORS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-11-19 | — | — | US | disclosed |
| US-10556860-B2 | hTERT modulators and methods of use | ARIZONA BOARD OF REGENTS (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180346415-A1 | hTERT MODULATORS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2018-12-06 | — | — | US | disclosed |
| EP-3383841-A1 | hTERT MODULATORS AND METHODS OF USE | The Arizona Board of Regents On Behalf of the University of Arizona (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017095969-A1 | hTERT MODULATORS AND METHODS OF USE | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-06-08 | — | — | WO | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| WO-2004071507-A1 | TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2004-08-26 | — | — | WO | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004048347-A1 | 1,2,4-TRIAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CJ CORPORATION (KR) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1086064-A2 | DIRECTED COMBINATORIAL COMPOUND LIBRARY AND HIGH THROUGHPUT ASSAYS FOR SCREENING SAME | Glycodesign Inc. (CA) | 2001-03-28 | — | — | EP | disclosed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-1999064378-A2 | DIRECTED COMBINATORIAL COMPOUND LIBRARY AND HIGH THROUGHPUT ASSAYS FOR SCREENING SAME | GLYCODESIGN INC. (CA) | 1999-12-16 | — | — | WO | disclosed |
| WO-1995033711-A1 | PHENYL BENZOYL(NICOTINOYL) UREA DERIVATIVES | HANWHA CORPORATION (KR) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361860-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | CES2 4208/4885CES1 2844/4885CA1 4389/4885 |
| US-10556860-B2 | hTERT modulators and methods of use | TERT, POT1, TERF2 | CES2 4566/4885CES1 3674/4885CA1 4124/4885 |
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | CES2 4014/4885CES1 3386/4885CA1 4573/4885 |
| US-20180346415-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, POT1, TERF2 | CES2 4566/4885CES1 3674/4885CA1 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.